— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement — ...
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei’s Board of Directors granted three new employees options to purchase...
First patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer Topline Phase 2 data in patients with advanced endometrial cancer expected in second...
PIKTOR is an investigational all-oral, multi-node inhibitor targeting escape routes in the PI3K/AKT/mTOR pathway that single-node inhibitors leave open
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16 th , 2026 at...
Faeth acquisition adds PIKTOR, an all-oral combination product candidate targeting multiple nodes of the PI3K/AKT/mTOR pathway $200 million private placement supports...
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on March 11, 2026, Sensei’s Board of Directors granted a new employee an option to purchase 166,435 shares of the Company’s...
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on February 19, 2026, Sensei’s Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893...
Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancer ...
BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery...